Bioenergetic Collapse

The third volume of the Collapse Trilogy, and the corpus's account of Phase I — the decades-long, clinically silent stage that runs from roughly the third decade of life.

Why it was written

The two prior theses identified a single upstream event — loss of the TGF-β/SMAD-maintained homeostatic microglial signature — as the generator of both attack and failure phenotypes, and identified the perineuronal net around parvalbumin interneurons as the substrate where the two become identical. But both leaned on "metabolic fitness", "oxidative senescence" and "failed salvage" as load-bearing variables without specifying the cell-biological machinery those terms require.

This thesis supplies that machinery. It is, in that sense, a repair to the trilogy's own foundations rather than an extension of its reach — the corpus noticing that its causal chain had a term in it doing work no one had defined.

The claim

Phase I is the erosion of mitochondrial and autophagy–lysosomal quality control in the locus coeruleus and the brainstem aminergic nuclei — the most metabolically extravagant and earliest-failing neurons in the human brain. The named drivers are PARP-1 hyperactivation, NAD⁺ depletion, and obstruction of mitochondrial protein import.

The logic is affordability rather than toxicity. A neuron that fires tonically, all day, for decades, is running a quality-control budget it must keep paying. When PARP-1 consumes NAD⁺ faster than dietary precursors can replace it, the budget fails — and it fails first in the cell with the highest standing cost.

Independent support for the ordering comes from outside the framework: multi-omics stratification across 4,089 samples found Proteostasis and energy metabolism to be the earliest impaired hallmarks in patients under 75, with immune activation and cell death appearing later.

Why it matters therapeutically

Phase I is preventive territory, not rescue territory. The window the thesis names is roughly age 20–50, and the drug class it nominates is the PARP inhibitors. That is a claim about timing as much as about mechanism: an agent aimed at Phase I biology and given in Phase III arrives decades after the phase it targets has closed, which the corpus treats as a structural explanation for trial failure rather than as bad luck.

Where to read it

The canonical treatment is research/collapse-trilogy/bioenergetic/, with a revised edition and supporting reviews of Chini on NAD⁺, Höglinger on Complex I, Rubinsztein on autophagy, and an evaluation of Bredesen. The narrative version is the Bioenergetic monograph.

Related

Homeostatic Microglial Collapse · Convergent Synaptic Collapse · Energy Metabolism · Proteostasis · Autophagic Flux · Locus coeruleus as ground zero · Cellular Senescence